BEAMSTART Logo

Samsung Bioepis gets EC's approval for Opuviz

Korea Economic Daily LogoKorea Economic Daily1h ago

Samsung Bioepis gets EC's approval for Opuviz - Korea Economic Daily

Quick Summary:

South Korea's Samsung Bioepis Co., Samsung Biologics Co.'s fully owned biosimilar subsidiary, and the US-based Biogen said on Tuesday the European Commission (EC) approved Opuviz (Aflibercept), its biosimilar to Beyer’s Eylea for the treatment of various eye diseases.

Opuviz is the second ophthalmology biosimilar approved in Europe and the fifth biosimilar in the portfolio developed by Samsung Bioepis with commercialization rights held by Biogen.

In November 2019, Samsung Bioepis and Biogen announced that they had entered a commercialization agreement for two ophthalmology biosimilar candidates, Byooviz and Opuviz in the US, Canada, and Europe.


More Pictures

Samsung Bioepis gets EC's approval for Opuviz - Korea Economic Daily (Picture 1)

or

Article Details

Category: Economy

Markets:

Topics:

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-11-19 @ 14:18:01 (1 hours ago)

News Timezone: GMT +8:00

News Source URL: kedglobal.com

Language: English

Article Length: 177 words

Reading Time: 1 minutes read

Sentences: 12 lines

Sentence Length: 15 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Korea Economic Daily

News ID: 23689776

View Article Analysis

About Korea Economic Daily

Korea Economic Daily Logo

Main Topics: Economy

Official Website: kedglobal.com

Update Frequency: 14 posts per day

Year Established: 1964

Headquarters: South Korea

News Last Updated: ago

Coverage Areas: South Korea

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #91

Publisher Details

Frequently Asked Questions

How long will it take to read this news story?

The story "Samsung Bioepis gets EC's approval for Opuviz" has 177 words across 12 sentences, which will take approximately 1 - 2 minutes for the average person to read.

Which news outlet covered this story?

The story "Samsung Bioepis gets EC's approval for Opuviz" was covered 1 hours ago by Korea Economic Daily, a news publisher based in South Korea.

How trustworthy is 'Korea Economic Daily' news outlet?

Korea Economic Daily is a fully independent (privately-owned) news outlet established in 1964 that covers mostly economy news.

The outlet is headquartered in South Korea and publishes an average of 14 news stories per day.

It's most recent story was published ago.

What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
  • News ID: #23689776
  • URL: https://beamstart.com/news/samsung-bioepis-gets-ecs-approval-17319940216523

BEAMSTART

BEAMSTART is a global entrepreneurship community, serving as a catalyst for innovation and collaboration. With a mission to empower entrepreneurs, we offer exclusive deals with savings totaling over $1,000,000, curated news, events, and a vast investor database. Through our portal, we aim to foster a supportive ecosystem where like-minded individuals can connect and create opportunities for growth and success.

© Copyright 2024 BEAMSTART. All Rights Reserved.